Daxdilimab clinical trials
Also written HZN-7734 and VIB7734.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses daxdilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses daxdilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)CompletedPhase 2AmgenNCT05669014Written as Daxdilimab
- Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus ErythematosusTerminatedPhase 2AmgenNCT05591222Written as Daxdilimab
- Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)TerminatedPhase 2AmgenNCT05540665Written as Daxdilimab
- Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia AreataCompletedPhase 2AmgenNCT05368103Written as Daxdilimab
- A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune DiseasesCompletedPhase 1AmgenNCT02780674Written as MEDI7734
- A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and DermatomyositisCompletedPhase 1AmgenNCT03817424Written as VIB7734
- Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension StudyTerminatedPhase 2AmgenNCT05430854Written as Daxdilimab
- Study of VIB7734 for the Treatment of Moderate to Severely Active SLECompletedPhase 2AmgenNCT04925934Written as VIB7734
- Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 InfectionTerminatedPhase 1Viela BioNCT04526912Written as VIB7734
Codes
What other systems call daxdilimab · ClinicalTrials.gg INT016240
- UNII (FDA) CNI3N6QR71DAXDILIMABOne source FDA
- NCI Thesaurus C174660DaxdilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CNI3N6QR71 | DAXDILIMAB | One source FDA |
| NCI Thesaurus | C174660 | Daxdilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.